New discovery to aid in diagnosis and treatment of kidney disease
July 1, 2009Researchers from Boston University School of Medicine (BUSM) in collaboration with scientists at the University of Louisville and the University of Nice Sophia Antipolis in France, have identified the target antigen PLA2R in patients with idiopathic membranous nephropathy (kidney disease), which has implications for the diagnosis and treatment of this disease. These findings appear in the July 2 issue of the New England Journal of Medicine.
Idiopathic membranous nephropathy involves the thickening and dysfunction of the filtering parts of the kidneys called glomeruli. It is caused when antibodies attack the glomeruli causing large amounts of protein to leak into the urine. It is a relatively common cause of adult-onset kidney disease that can progress over time to cause kidney failure. Until now, the diagnosis of membranous nephropathy required a kidney biopsy as there are no blood or urine tests to specifically distinguish membranous nephropathy from other causes of kidney disease. This is because up until now the protein that is the target of the circulating auto-antibodies has never been identified.
To identify the target antigen in patients with this condition, the researchers used circulating antibodies from adults with this disease to detect normal glomerular proteins. Subsequent analysis with the use of mass spectrometry and confirmation with the use of protein-specific reagents allowed for identification and characterization of the predominant protein detected by these circulating antibodies.
According to the researchers this discovery has important implications for both the diagnosis and treatment of membranous nephropathy. "Identifying the antigen will enable development of a simple blood test that could replace the need for a kidney biopsy and establish which patients are most likely to benefit from immunosuppressive treatment," said senior author David Salant, MD, a professor of medicine at BUSM and chief of the renal section at Boston Medical Center.
"Our findings show that PLA2R is a major target antigen in idiopathic membranous nephropathy. Seventy percent of our patients with biopsy-proven idiopathic membranous nephropathy had IgG antibodies that reacted with PLA2R, a constituent of normal human glomeruli," he added.
Source: Boston University Medical Center
-
New urine test detects common cause of kidney transplant failure
Jan 21, 2009 |
not rated yet |
0
-
Uric acid may provide early clues to diabetic kidney disease
Mar 18, 2008 |
not rated yet |
0
-
Discovery could lead to much-needed kidney failure treatment
Mar 12, 2008 |
not rated yet |
0
-
Receptor protein appears to be key in breakdown of kidney filtration
Dec 19, 2007 |
not rated yet |
0
-
Combination therapy stops loss of kidney function in rare genetic disease
Jul 26, 2007 |
not rated yet |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (30) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (3) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (1) |
0
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Team isolates nerve cells involved in storing long term memory and gene proteins associated with them
(Medical Xpress) -- A research team in Taiwan has succeeded in isolating two nerve cells in fruit fly brains that are believed to be the major players in allowing for the formation of long term memories. Furthermore, ...
News of plaque-clearing drug tops week of major advances against Alzheimer's disease
In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease. At the same time, the White House and members of Congress are proposing increases in Alzheimer's research ...
51 minutes ago |
not rated yet |
1
To avoid early labor and delivery, weight and diet changes not the answer
One of the strongest known risk factors for spontaneous or unexpected preterm birth any birth that occurs before the 37th week of pregnancy, most often without a known cause is already having had one. For women ...
4 minutes ago |
not rated yet |
0
|
Joint patent for using the BRCA1 gene as a therapy for cardiovascular disease
St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.
20 minutes ago |
not rated yet |
0
S.Africa in $208 mln AIDS drug venture with Swiss Lonza
South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.
Medicine & Health / HIV & AIDS
1 hour ago |
not rated yet |
0
The power of estrogen -- male snakes attract other males
A new study has shown that boosting the estrogen levels of male garter snakes causes them to secrete the same pheromones that females use to attract suitors, and turned the males into just about the sexiest ...
Could Venus be shifting gear?
(PhysOrg.com) -- ESAs Venus Express spacecraft has discovered that our cloud-covered neighbour spins a little slower than previously measured. Peering through the dense atmosphere in the infrared, the ...
Experts reveal how plants don't get sunburn
(PhysOrg.com) -- Experts at the University of Glasgow have discovered how plants survive the harmful rays of the sun.
Fool's gold may prove an unlikely alternative to overexploited catalytic materials
Catalytic materials, which lower the energy barriers for chemical reactions, are used in everything from the commercial production of chemicals to catalytic converters in car engines. However, with current catalytic materials ...
SLAC, Stanford team focuses on high-energy electrons to treat cancer
Accelerator physicists at SLAC and cancer specialists from Stanford are working on a new technology that could dramatically reduce the time needed for cancer radiation treatments. The team ran an initial experiment ...
Unpicking HIV’s invisibility cloak
Drug researchers hunting for alternative ways to treat human immunodeficiency virus (HIV) infections may soon have a novel targetits camouflage coat. HIV hides inside a cloak unusually rich in a sugar ...